NASDAQ: OCSOculis Holding Ag Stock
$6.99+0.00 (+0%)
Updated Mar 27, 2023
OCS Price
$6.99
Fair Value Price
N/A
Market Cap
$114.63M
52 Week Low
$6.26
52 Week High
$14.10
P/E
349.5x
P/B
-14.22x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$342.90k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.06
Operating Cash Flow
-$515k
Beta
0.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OCS Overview
European Biotech Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets opportunities in the life sciences industry in Europe. European Biotech Acquisition was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCS was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OCS is poor value based on its earnings relative to its share price (349.5x), compared to the US market average (21.44x)
P/E vs Market Valuation
OCS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more OCS due diligence checks available for Premium users.
Be the first to know about important OCS news, forecast changes, insider trades & much more!
OCS News
Valuation
OCS fair value
Fair Value of OCS stock based on Discounted Cash Flow (DCF)
Price
$6.99
Fair Value
$10.77
Undervalued by
35.11%
OCS was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
349.5x
Industry
18.55x
Market
21.44x
OCS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
OCS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
OCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-14.22x
Industry
4.86x
OCS's financial health
Profit margin
Revenue
$0.0
Net Income
-$968.7k
Profit Margin
0%
OCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$129.8M
Liabilities
$8.5M
Debt to equity
-1.06
OCS's short-term liabilities ($795.57k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCS's long-term liabilities ($7.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$80.9k
Investing
$0.0
Financing
-$45.0k
OCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCS vs Biotech Stocks
Oculis Holding Ag Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.